Skip to content

Study · Not a test of the peptide alone · 2022

1 result

Unique Deep Radiomic Signature Shows NMN Treatment Reverses Morphology of Oocytes from Aged Mice.

Habibalahi A, Campbell JM, Bertoldo MJ, Mahbub SB, Goss DM, Ledger WL, Gilchrist RB, Wu LE, Goldys EM

Biomedicines29 Jun 2022Cited by 13 (Europe PMC)

PMID35884850 (opens in a new tab)PMCIDPMC9313081 (opens in a new tab)DOI10.3390/biomedicines10071544 (opens in a new tab)PepBankPUB-35884850
Download PDFPubMedAsk about this study
Jump to 1 result

Summary

The purpose of this study is to develop a deep radiomic signature based on an artificial intelligence (AI) model. This radiomic signature identifies oocyte morphological changes corresponding to reproductive aging in bright field images captured by optical light microscopy. Oocytes were collected from three mice groups: young (4- to 5-week-old) C57BL/6J female mice, aged (12-month-old) mice, and aged mice treated with the NAD+ precursor nicotinamide mononucleotide (NMN), a treatment recently shown to rejuvenate aspects of fertility in aged mice. We applied deep learning, swarm intelligence, and discriminative analysis to images of mouse oocytes taken by bright field microscopy to identify a highly informative deep radiomic signature (DRS) of oocyte morphology. Predictive DRS accuracy was determined by evaluating sensitivity, specificity, and cross-validation, and was visualized using scatter plots of the data associated with three groups: Young, old and Old + NMN. DRS could successfully distinguish morphological changes in oocytes associated with maternal age with 92% accuracy (AUC~1), reflecting this decline in oocyte quality. We then employed the DRS to evaluate the impact of the treatment of reproductively aged mice with NMN. The DRS signature classified 60% of oocytes from NMN-treated aged mice as having a 'young' morphology. In conclusion, the DRS signature developed in this study was successfully able to detect aging-related oocyte morphological changes. The significance of our approach is that DRS applied to bright field oocyte images will allow us to distinguish and select oocytes originally affected by reproductive aging and whose quality has been successfully restored by the NMN therapy.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking NMN (nicotinamide mononucleotide).

  1. 01Computer modelNot a test of NMN (nicotinamide mononucleotide) aloneIn silicoEfficacy outcome

    In NMN-treated aged mice, the radiomic signature classified 60% of oocytes as having young morphology.

    In plain wordsIn computer analysis, the image signature classified 60% of oocytes from NMN-treated aged mice as having young morphology.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Not applicableOocytes classified as young morphology
    Study

    mousen: not reported in source

    aged C57BL/6J female mice
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Measurements

    Oocytes classified as young
    60%
    NMN-treated aged mice

    Source sentences

    Summary
    The DRS signature classified 60% of oocytes from NMN-treated aged mice as having a 'young' morphology.
    1 context sentence
    Summary · context
    Oocytes were collected from three mice groups: young (4- to 5-week-old) C57BL/6J female mice, aged (12-month-old) mice, and aged mice treated with the NAD+ precursor nicotinamide mononucleotide (NMN), a treatment recently shown to rejuvenate aspects of fertility in aged mice.

    In this study, NMN (nicotinamide mononucleotide) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking NMN (nicotinamide mononucleotide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.